Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of DSP-5336 in Advanced Hematologic Malignancies
NCT07444268Phase 1Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Mar 2026
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of enzomenib in hematologic malignancy (2 arms), sponsored by Sumitomo Pharma America. Primary endpoints: Total recovery of radioactivity in urine as percentage of total radioactive dose of [14C]-DSP-5336 at Day 7, Total recovery of radioactivity in fecal waste as percentage of total radioactive dose of [14C]-DSP-5336 at Day 7 and 2 more. Started Mar 2026; status: completed.
02
Drugs
enzomenib
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT07444268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444268.